NICE commissioned an external assessment centre (EAC) to review the evidence submitted by the company. This section summarises that review. Full details of all the evidence are in the project ...
Treatment with the recently approved, minimally invasive Optilume BPH device improves urinary symptoms while preserving sexual function in men with benign prostatic hyperplasia (BPH), concludes a ...
PORTSMOUTH, N.H., Jan. 17, 2025 /PRNewswire/ -- Laborie Medical Technologies Corp. (Laborie), a leader in diagnostic and therapeutic medical technologies, has reached a significant milestone with its ...
Findings Published in Journal of Endourology Support Minimally Invasive Alternative to Repeat Endoscopic Procedures PORTSMOUTH, N.H., May 8, 2025 /PRNewswire/ -- Laborie Medical Technologies Corp.
Treatment with the recently approved, minimally invasive Optilume BPH device improves urinary symptoms while preserving sexual function in men with benign prostatic hyperplasia (BPH), concludes a ...
The US Food and Drug Administration has approved a new catheter designed to treat urinary tract symptoms of an enlarged prostate, also known as benign prostate hyperplasia (BPH). Designed and marketed ...
The committee noted that the clinical evidence showed Optilume to be effective in improving clinically relevant outcomes including anatomical success, peak flow rate and international prostate symptom ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results